Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Stock Exchange of Hong Kong  >  Innovent Biologics Inc    1801   KYG4818G1010

INNOVENT BIOLOGICS INC

(1801)
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Drugmakers slash prices in China to get on reimbursement list

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/28/2019 | 02:10am EST
FILE PHOTO: Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration

Drugmakers including Roche and Novartis have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.

Addition to the list is likely to boost sales volume by opening up markets in smaller and less-affluent Chinese cities, but some industry insiders have cautioned that only offering deep price cuts in China could spark criticism of the drugmakers in other markets.

Seventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis dermatitis treatment Omalizumab, branded as Xolair, will be added to the list, the National Healthcare Security Administration said on its website on Thursday.

Chinese patients are allowed to use their state medical insurance to cover a significant portion of the cost of drugs named on the list.

Almost all the imported drugs added to the list in the latest update had the "lowest prices globally", the NHSA said in its statement.

"China is and will be the ultimate high-volume, low-price market, and so international companies feel that they'll have to take a big pay cut but make up for the volume," Brad Loncar, chief executive of biopharma sector-dedicated Loncar Investments, told Reuters.

Tumor and diabetes medicines saw an average price cut of about 65%, according to the NHSA.

Other drugs added included Adalimumab, an arthritis treatment which AbbVie sells as Humira, one the top-selling drugs in the world.

Also included was cancer treatment Tyvyt, or Sintilimab, co-developed by Chinese drugmaker Innovent Biologics and Eli Lilly. It is considered to be a PD-1/PD-L1 treatment, a category of novel drugs that work on the immune system to fight cancer cells.

China has already approved five PD-1/PD-L1 treatments, including two top-selling global blockbusters made by foreign firms Bristol-Myers Squibb and Merck. However neither have been added to the list.

Analysts say domestically developed Tyvyt's early inclusion could give it an advantage over its foreign rivals.

"Maybe (Chinese PD-1/PD-L1 products) don't come in and compete on day one with international (pharmas) in all indications, but just getting a foot in the door might already be a big step for them," UBS analyst Michael Leuchten told Reuters before the NHSA announcement.

By Roxanne Liu and Brenda Goh

Stocks mentioned in the article
ChangeLast1st jan.
INNOVENT BIOLOGICS INC End-of-day quote.
NOVARTIS -0.71% 90.51 Delayed Quote.22.87%
ROCHE HOLDING AG -1.07% 300.15 Delayed Quote.25.45%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INNOVENT BIOLOGICS INC
12/05INNOVENT BIOLOGICS : Announces First Patient Dosed in Phase I Clinical Trial of ..
PR
12/05INNOVENT BIOLOGICS : Voluntary announcement - first patient dosed in a phase i c..
PU
12/04INNOVENT BIOLOGICS : Grant of share options and restricted shares
PU
12/01INNOVENT BIOLOGICS : Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab ..
PR
12/01INNOVENT BIOLOGICS : Announces FDA Acceptance of NDA for Pemigatinib in Patients..
PR
11/28Drugmakers slash prices in China to get on reimbursement list
RE
11/27INNOVENT BIOLOGICS : Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor ..
PR
11/27INNOVENT BIOLOGICS : Inside information announcement - tyvyt (sintilimab injecti..
PU
11/26INNOVENT BIOLOGICS : Announces First Patient Dosed in Phase I Clinical Trial of ..
PR
11/26INNOVENT BIOLOGICS : Voluntary announcement - first patient dosed in a phase i c..
PU
More news
Financials (CNY)
Sales 2019 779 M
EBIT 2019 -1 452 M
Net income 2019 -1 499 M
Finance 2019 1 924 M
Yield 2019 -
P/E ratio 2019 -21,3x
P/E ratio 2020 -29,6x
EV / Sales2019 38,0x
EV / Sales2020 16,5x
Capitalization 31 557 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 29,87  CNY
Last Close Price 25,09  CNY
Spread / Highest target 26,7%
Spread / Average Target 19,1%
Spread / Lowest Target 5,57%
EPS Revisions
Managers
NameTitle
De Chao Yu Chairman, President & Chief Executive Officer
Qin Wei Zhou Chief Operations Officer
Hao Xi Ede Chief Financial Officer & Executive Director
Kerry L. Blanchard Chief Science Officer
Jessie Chen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
INNOVENT BIOLOGICS INC4 483
CSL LIMITED50.11%86 193
BIOGEN INC.-1.78%53 330
ALEXION PHARMACEUTICALS15.53%24 891
SAMSUNG BIOLOGICS CO LTD--.--%21 570
GRIFOLS36.20%20 629